Trastuzumab deruxtecan, another ADC, received accelerated tumor-agnostic approval for cancers expressing 3 + HER2 immunohistochemistry (IHC) in April 2024 based on the series of DESTINY trials (Kemp, 2024). The gene discussed is ERBB2; the disease is neoplasm.